Showing results (71-80 of 81) with videos related to
Sort By:
Pageof 9
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 27, 2025
PET- and CT-Based Imaging Criteria for Response Assessment of Gastroenteropancreatic Neuroendocrine Tumors Under Radiopharmaceutical TherapyFelix L Herr, Christian Dascalescu, Matthias P Fabritius, et al.Journal of Vascular and Interventional Radiology : JVIR|July 24, 2024
Immune Modulation in Untreated, Contralateral Hepatic Metastases after Yttrium-90 Radioembolization of Microsatellite Stable Colorectal CancerElif Öcal, Marianna Alunni-Fabbroni, Ignazio Piseddu, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 29, 2026
PET-Based Outcome Prediction in Patients with Prostate Cancer Scheduled for [<sup>225</sup>Ac]Ac-PSMA Radiopharmaceutical TherapyLiam Widjaja, Sophie C Siegmund, Franz J Gildehaus, et al.Frontiers in Oncology|June 7, 2021
Feasibility of Different Tumor Delineation Approaches for <sup>18</sup>F-PSMA-1007 PET/CT Imaging in Prostate Cancer PatientsLena M Mittlmeier, Matthias Brendel, Leonie Beyer, et al.EJNMMI Reports|August 18, 2024
PSMA-PET/CT response after metastasis-directed radiotherapy of bone oligometastases in prostate cancerGabriel T Sheikh, Christian Trapp, Nina-Sophie Schmidt-Hegemann, et al.European Journal of Nuclear Medicine and Molecular Imaging|September 19, 2025
[<sup>18</sup>F]SiTATE PET for PRRT selection and monitoring metastatic tumors of the adrenal medulla and extra-adrenal paragangliaSophie C Siegmund, Adrien Holzgreve, Magdalena Schöll, et al.European Journal of Nuclear Medicine and Molecular Imaging|June 11, 2026
Effects of androgen receptor signaling inhibitors on absorbed doses in mCRPC patients undergoing [<sup>177</sup>Lu]Lu-PSMA-617 or [<sup>177</sup>Lu]Lu-PSMA-I&T therapy: dosimetry resultsJosef Zahner, Astrid Delker, Zachary Ells, et al.Theranostics|June 16, 2025
Association of integrated biomarkers and progression-free survival prediction in patients with gastroenteropancreatic neuroendocrine tumors undergoing [177Lu]Lu-DOTA-TATE therapyFelix L Herr, Christian Dascalescu, Ricarda Ebner, et al.Biomedicines|May 28, 2022
Total Tumor Volume on <sup>18</sup>F-PSMA-1007 PET as Additional Imaging Biomarker in mCRPC Patients Undergoing PSMA-Targeted Alpha Therapy with <sup>225</sup>Ac-PSMA-I&TLena M Unterrainer, Leonie Beyer, Mathias J Zacherl, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 24, 2025
Evidence-Based Clinical Protocols to Monitor Efficacy of [<sup>177</sup>Lu]Lu-PSMA Radiopharmaceutical Therapy in Metastatic Castration-Resistant Prostate Cancer Using Real-World DataLena M Unterrainer, Nicolas De Leiris, Marcus Unterrainer, et al.Pageof 9